Collegium Net Income From Continuing Ops from 2010 to 2026
| COLL Stock | USD 45.79 0.51 1.13% |
Net Income From Continuing Ops | First Reported 2013-12-31 | Previous Quarter 12 M | Current Value 31.5 M | Quarterly Volatility 28.5 M |
Check Collegium Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collegium Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 204.3 M, Interest Expense of 89.3 M or Selling General Administrative of 105.2 M, as well as many indicators such as Price To Sales Ratio of 1.6, Dividend Yield of 0.0721 or PTB Ratio of 5.12. Collegium financial statements analysis is a perfect complement when working with Collegium Pharmaceutical Valuation or Volatility modules.
Collegium | Net Income From Continuing Ops | Build AI portfolio with Collegium Stock |
Historical Net Income From Continuing Ops data for Collegium Pharmaceutical serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Collegium Pharmaceutical represents a compelling investment opportunity.
Latest Collegium Pharmaceutical's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Collegium Pharmaceutical over the last few years. It is Collegium Pharmaceutical's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Collegium Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Collegium Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 352,731 | |
| Coefficient Of Variation | 15,158 | |
| Mean Deviation | 44,307,416 | |
| Median | (17,917,000) | |
| Standard Deviation | 53,467,184 | |
| Sample Variance | 2858.7T | |
| Range | 177.7M | |
| R-Value | 0.67 | |
| Mean Square Error | 1666.5T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | 7,130,115 | |
| Total Sum of Squares | 45739.8T |
Collegium Net Income From Continuing Ops History
About Collegium Pharmaceutical Financial Statements
Collegium Pharmaceutical investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Collegium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 79.6 M | 83.5 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Collegium Pharmaceutical Correlation against competitors. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 2.132 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 0.314 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.